Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data from a new test discovered by the Company to assess the risk of cancer recurrence in patients diagnosed with soft tissue sarcomas (STS). Results were presented in a poster session at the Connective Tissue Oncology Society Annual Meeting, November 4-7, 2015 in Salt Lake City.
Read More →
